KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.95

The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC).

Ramesh Omranipour, Bita Eslami, Sadaf Alipour, Newsha Nazarian, Farhad Shahi, Mehrzad Mirzania, Khatereh Mousavi, Ahmad Elahi, Mahtab Vasigh

Ann Surg Oncol 10.1245/s10434-026-20187-1

PMID42472751
PMCID-
DOI10.1245/s10434-026-20187-1
发表日期2026-07-19
入排依据:Original Phase III randomized trial evaluating locoregional treatment versus systemic therapy in de novo metastatic breast cancer, with primary OS endpoint. The study is drug-containing (systemic therapy is the comparator and maintenance treatment).
图像/No. at risk 复核:未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Less than 10% of breast cancer patients have distant metastatic lesions (DnMBC) at the time of diagnosis. The overall survival (OS) of this group has been prolonged by advances in systemic therapies (ST) in recent decades. This study aimed to evaluate the role of locoregional treatment (LRT) in de novo metastatic breast cancer (DnMBC), which is non-progressive under ST. METHODS: The DnMBC patients who did not progress under ST were randomized to LRT and ST groups. The LRT group underwent a free-margin lumpectomy or mastectomy and axillary surgery with or without adjuvant radiotherapy. All the patients received maintenance ST thereafter and were visited every 3 months. The primary endpoint was OS. RESULTS: Between 2018 and 2023, 250 patients were randomly assigned between the LRT (n = 158) and ST (n = 92) groups. The two groups were similar in terms of age and subtype. A 2-year OS of 81% and a 5-year OS of 43% were observed in the entire cohort. The estimated median time to death was 53 months (95% confidence interval [CI], 45-61 months) in the LRT group and 55 months (95% CI, 44-66 months) in the ST group. The log-rank test (p = 0.6) and adjusted Cox regression (hazard ratio [HR], 0.08; 95% CI, 0.9-1.3; p = 0.35) showed no OS differences between the LRT and ST groups. Patients with human epidermal growth factor receptor 2 (HER2+) (HR, 1.86; 95% CI, 1.21-2.87; p = 0.005) and lung metastasis (HR, 1.5, 95% CI, 1.04-2.26, p = 0.03) had an increased risk of death. CONCLUSION: In DnMBC, LRT is not associated with improved OS. Those with lung metastasis and HER2+ disease had a higher risk of death.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。